Inhibrx Biosciences (INBX) Gains from Investment Securities (2023 - 2025)
Inhibrx Biosciences (INBX) reported Gains from Investment Securities of $2000.0 for Q4 2025, up 100.06% year-over-year from $999.72 in Q4 2024, and up 200.0% quarter-over-quarter from -$2000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Gains from Investment Securities (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Gains from Investment Securities data on file, last reported at $2000.0 in Q4 2025.
- Gains from Investment Securities for Q4 2025 came in at $2000.0, up 100.06% year-over-year; the trailing twelve-month figure through Dec 2025 was $2000.0 (changed 0.0% YoY), and the FY2025 annual result was $2000.0, changed 0.0% from the prior year.
- Gains from Investment Securities rose to $2000.0 in Q4 2025 per INBX's latest filing, from -$2000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $3.6 million in Q2 2024 and troughed at -$3.5 million in Q4 2024.
- A 3-year average of $205000.0 and a median of $2000.0 in 2023 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities slumped 1750.0% in 2024, then surged 100.06% in 2025.
- A 3-year view of Gains from Investment Securities shows it stood at $1.6 million in 2023, then slumped by 317.01% to -$3.5 million in 2024, then surged by 100.06% to $2000.0 in 2025.
- Business Quant data shows INBX's Gains from Investment Securities at $2000.0 in Q4 2025, -$2000.0 in Q3 2025, and $2000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Dec 31, 2024 | -3.55 Mn |
| Dec 31, 2024 | -3.55 Mn |
| Sep 30, 2024 | -33,000.00 |
| Sep 30, 2024 | -33,000.00 |
| Jun 30, 2024 | 3.58 Mn |
| Jun 30, 2024 | 3.58 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Sep 30, 2023 | 2,000.00 |
| Sep 30, 2023 | 2,000.00 |